Related Experiment Video

Updated: Apr 6, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

In vitro anti-platelet potency of ticagrelor in blood samples from infants and children

Fredrik Söderlund1, Anna-Karin Asztély2, Anders Jeppsson3

  • 1Department of Paediatric Anaesthesia and Intensive Care, Queen Silvia's Children Hospital, Gothenburg, Sweden.

Thrombosis Research
|July 27, 2015
PubMed

Insights

Ticagrelor, a P2Y12 receptor inhibitor, showed comparable anti-platelet potency in vitro across all pediatric age groups and adults. This suggests similar efficacy in children and adults at equivalent plasma concentrations.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Cardiovascular Research

Background:

  • Ticagrelor is an approved P2Y12 receptor antagonist for acute coronary syndrome in adults.
  • The anti-platelet effects of ticagrelor in pediatric populations remain unexplored.
  • This study investigates age-related differences in ticagrelor's in vitro potency.

Purpose of the Study:

  • To evaluate the in vitro anti-platelet potency of ticagrelor in pediatric blood samples across various age groups.
  • To compare the potency of ticagrelor in children with that observed in adult blood samples.
  • To establish a baseline for potential ticagrelor efficacy in pediatric patients.

Main Methods:

  • Blood samples were collected from 36 healthy children (grouped by age) and 13 adults.
  • In vitro analysis included vasodilator stimulated phosphoprotein phosphorylation (VASP) assay and ADP-induced light transmission aggregometry (LTA).
  • Ticagrelor's potency was assessed by calculating the IC50 (concentration for 50% inhibition).

Main Results:

  • The in vitro potency of ticagrelor was comparable between adult blood samples and blood samples from all pediatric age groups.
  • Both LTA and VASP assays demonstrated similar ticagrelor potency across all tested age demographics.
  • No significant age-dependent variations in ticagrelor's anti-platelet effect were observed in vitro.

Conclusions:

  • In vitro findings suggest ticagrelor exhibits comparable anti-platelet potency in children of all ages compared to adults.
  • These results support the hypothesis that ticagrelor may achieve similar therapeutic effects in pediatric patients as in adults at equivalent plasma exposures.
  • Further clinical studies are warranted to confirm these findings in pediatric populations.
Abstract

Keywords:
ADP receptorsPaediatric haemostasisPlatelet pharmacologyTicagrelor

More Related Videos

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers05:43

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers

Published on: November 8, 2024

924
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.6K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
762
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
817